{"id":"placebo-pbo-oral-capsules","safety":{"commonSideEffects":[{"rate":"variable, typically 10–40% depending on condition and trial design","effect":"Placebo effect (symptom improvement without active drug)"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo works through psychological and neurobiological mechanisms including expectation, conditioning, and activation of endogenous pain-relief and reward pathways. It is used as a control comparator in clinical trials to distinguish the true pharmacological efficacy of an investigational drug from non-specific effects. Placebo can produce measurable clinical improvements in subjective symptoms, particularly pain, nausea, and fatigue, through mind-body interactions.","oneSentence":"Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:18.997Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials (non-therapeutic use)"}]},"trialDetails":[{"nctId":"NCT02069366","phase":"NA","title":"Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2014-11","conditions":"Post-Traumatic Stress Disorder","enrollment":86},{"nctId":"NCT03008005","phase":"PHASE4","title":"Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2017-06-01","conditions":"PostTraumatic Stress Disorder","enrollment":46},{"nctId":"NCT04080427","phase":"PHASE1","title":"Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study","status":"COMPLETED","sponsor":"Wayne State University","startDate":"2021-04-15","conditions":"Posttraumatic Stress Disorder","enrollment":102},{"nctId":"NCT05066672","phase":"PHASE2","title":"Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression","status":"COMPLETED","sponsor":"Navitor Pharmaceuticals, Inc.","startDate":"2022-02-28","conditions":"Treatment Resistant Depression","enrollment":400},{"nctId":"NCT01107496","phase":"PHASE1, PHASE2","title":"Evaluation of Immediate-Release Viloxazine in Adults With ADHD","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2010-06","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":52},{"nctId":"NCT04913610","phase":"PHASE2","title":"Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection","status":"TERMINATED","sponsor":"AbbVie","startDate":"2021-05-22","conditions":"Onchocerciasis","enrollment":153},{"nctId":"NCT04659161","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)","status":"COMPLETED","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2020-12-16","conditions":"Schizophrenia, Schizophrenia; Psychosis","enrollment":252},{"nctId":"NCT02563769","phase":"PHASE1","title":"Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study","status":"COMPLETED","sponsor":"Temple University","startDate":"2016-10-24","conditions":"Cocaine Dependence, Cocaine Addiction, Cocaine Abuse","enrollment":10},{"nctId":"NCT03811847","phase":"PHASE4","title":"A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-11-01","conditions":"Alzheimer Dementia","enrollment":11},{"nctId":"NCT04405739","phase":"PHASE2","title":"The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)","status":"COMPLETED","sponsor":"Ridgeback Biotherapeutics, LP","startDate":"2020-06-16","conditions":"SARS-CoV 2","enrollment":71},{"nctId":"NCT04016779","phase":"PHASE3","title":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2019-11-20","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":374},{"nctId":"NCT04405570","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","status":"COMPLETED","sponsor":"Ridgeback Biotherapeutics, LP","startDate":"2020-06-19","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":204},{"nctId":"NCT02633527","phase":"PHASE2","title":"Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2016-02-01","conditions":"Attention-Deficit/Hyperactivity Disorder (ADHD)","enrollment":222},{"nctId":"NCT03247543","phase":"PHASE3","title":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2017-10-31","conditions":"ADHD","enrollment":313},{"nctId":"NCT03247556","phase":"PHASE3","title":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2017-11-20","conditions":"ADHD","enrollment":297},{"nctId":"NCT03247530","phase":"PHASE3","title":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2017-10-20","conditions":"ADHD","enrollment":477},{"nctId":"NCT03247517","phase":"PHASE3","title":"Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD","status":"COMPLETED","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2017-11-02","conditions":"ADHD","enrollment":310},{"nctId":"NCT01425203","phase":"PHASE3","title":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-11-23","conditions":"Chronic Hepatitis C Genotype 1","enrollment":238},{"nctId":"NCT03627494","phase":"PHASE1","title":"First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-30","conditions":"Muscular Dystrophies","enrollment":66},{"nctId":"NCT02787304","phase":"PHASE2","title":"Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)","status":"TERMINATED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2016-10-24","conditions":"Non-Alcoholic Steatohepatitis","enrollment":197},{"nctId":"NCT01092780","phase":"PHASE1","title":"Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-26","conditions":"Apnea, Sleep","enrollment":56},{"nctId":"NCT00874939","phase":"PHASE1","title":"A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-06","conditions":"Alzheimer's Disease, Dementia","enrollment":4},{"nctId":"NCT00704405","phase":"PHASE2","title":"Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-27","conditions":"Hepatitis C, Chronic","enrollment":285},{"nctId":"NCT01025843","phase":"PHASE1","title":"Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12-01","conditions":"Hypertension","enrollment":20},{"nctId":"NCT02652377","phase":"PHASE1","title":"EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients","status":"COMPLETED","sponsor":"Enanta Pharmaceuticals, Inc","startDate":"2016-01-10","conditions":"Hepatitis C","enrollment":100},{"nctId":"NCT01341925","phase":"PHASE1","title":"Omega-3 and Therapy Study for Depression","status":"COMPLETED","sponsor":"L. Eugene Arnold","startDate":"2011-09","conditions":"Depression","enrollment":73},{"nctId":"NCT01507753","phase":"PHASE1","title":"Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified","status":"COMPLETED","sponsor":"L. Eugene Arnold","startDate":"2011-09","conditions":"Bipolar Disorder","enrollment":23},{"nctId":"NCT01157104","phase":"PHASE1","title":"A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06","conditions":"Chronic Hepatitis C","enrollment":20},{"nctId":"NCT00357994","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-01","conditions":"Advanced Parkinson's Disease","enrollment":36},{"nctId":"NCT00660387","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-12","conditions":"Advanced Parkinson's Disease","enrollment":35},{"nctId":"NCT01292239","phase":"PHASE3","title":"A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":183}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (PBO) oral capsules","genericName":"Placebo (PBO) oral capsules","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit. Used for Control arm in phase 3 clinical trials (non-therapeutic use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}